'In it for the long run': Tokalas merger building Oncternal's pipeline
By Jennifer Boggs
Friday, October 7, 2016
Earlier this year, the quiet joining of two recent San Diego-based startups led to the creation of Oncternal Therapeutics Inc., an oncology-focused firm boasting two potentially first-in-class drugs, both of which already have entered the clinic.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.